Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Price Up 4.2% – Here’s What Happened

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)’s share price traded up 4.2% during mid-day trading on Monday . The stock traded as high as $0.49 and last traded at $0.47. 74,451 shares changed hands during mid-day trading, an increase of 17% from the average session volume of 63,626 shares. The stock had previously closed at $0.45.

Hepion Pharmaceuticals Stock Down 31.4 %

The stock has a 50-day moving average of $0.57 and a 200 day moving average of $0.68.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hepion Pharmaceuticals stock. Anson Funds Management LP acquired a new stake in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 17.24% of the company’s stock.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.